During the 64th American Society of Hematology (ASH) Annual Meeting and Exposition, the Lymphoma Hub spoke to Chan Cheah, University of Western Australia, Perth, AU. We asked for an update on novel therapies in chronic lymphocytic leukemia (CLL). Cheah reviews the abstracts that were presented at ASH on novel BTK inhibitors and Bcl-2 inhibitors for relapsed/refractory CLL. This includes an analysis of the potency, toxicity, and MRD response rates of the Bcl-2 inhibitor, BGB-11417, as well as the results of the phase I/II BRUIN study of the non-covalent BTK inhibitor, pirtobrutinib, in heavily pretreated patients with CLL and patients with Richter’s transformation.

Ten years ago Rosemary was diagnosed with Chronic Lymphocytic Leukaemia (CLL). She shares her journey of how she has managed to live with this condition.

Hello and thank you for joining me here at the American Society of Clinical Oncology meeting 2016 in Chicago. My name is Srdan Verstovsek. I'm the Professor in the Leukemia Department at MD Anderson Cancer Center in Houston, Texas.

I'm going to review briefly the highlights of the CLL and Lymphoma sections that were presented here at the meeting with several reports deserving mention. The first one that I'd like to talk about is venetoclax, which was tested in relapsed refractory CLL patients after ibrutinib or idelalisib.

Silvia DEAGLIO, Department of Medical Sciences University of Turin & Human Genetics Foundation, Turin, ITALY speaks on "Tumor-host interactions in chronic lymphocytic leukemia: moving up a NOTCH?". This seminar has been recorded by ICGEB Trieste.

Alberto Orfao, MD, PhD, University of Salamanca, Salamanca, Spain, shares some insights into monoclonal B-cell lymphocytosis (MBL) in chronic lymphocytic leukemia (CLL), highlighting some important points to consider when investigating low-count and high-count MBL. First, Dr Orfao explains the importance of identifying low-count MBL patients with a high-risk of progression and the role that age plays in disease. Following this, Dr Orfao discusses the need to better understand why these clones appear in patients, and the potential role of the B-cell receptor in the development of MBL. To conclude, Dr Orfao explains the need to further investigate the consequences of having small clones of B-cells and the mechanisms involved in disease progression to CLL. This interview took place during the 2nd ESH Translational Research Conference on Chronic Lymphocytic Leukemia (ESH CLL), 2022.

Dr Tam is a Consultant Haematologist from Melbourne, Australia. He recently gave a presentation to our CLL support group in Auckland during which he explained the biology of CLL and also discussed treatment and side effects. Part 1 of 4

Leukemia is a group of blood cancers that usually begin in the bone marrow and result in high numbers of abnormal blood cells. These blood cells are not fully developed and are called blasts or leukemia cells. In 2015, leukemia was present in 2.3 million people worldwide and caused 353,500 deaths.

In this video, we have explained everything you need to know about leukemia.

0:00 What is leukemia?
0:39 Leukemia symptoms (Symptoms of leukemia)
1:13 Leukemia causes (Causes of leukemia)
1:57 Leukemia classification (Classification of leukemia)
2:11 Acute leukemia
2:26 Chronic leukemia
2:44 Lymphocytic leukemia & myelogenous leukemia
3:12 Leukemia types (Types of leukemia)
3:56 Risk factors of leukemia
4:15 Leukemia diagnosis (Diagnosis of leukemia)
5:13 Leukemia treatment (Treatment of leukemia)

Hope you will like the video, Please support us by subscribing to our channel. Also follow us on our Instagram and facebook.

#bloodcancer #bloodcancerawareness #leukemiaawareness #leukemia #leukemiatreatment